In this report, we present novel findings that implicate C/EBPα in regulating the expression and activity of calpain 3 in vivo and data showing a new physiological substrate for calpain 3: cyclin A. Our results demonstrate that cleavage of cyclin A by calpain 3 occurs in mouse and human myeloid precursor cells.
INTRODUCTION
Several transcription factors are master regulators of hematopoiesis, regulating the development of multi-potential precursor cells into terminally differentiated blood cells. In myeloid differentiation, several transcription factors have been shown to be key players, including PU.1, AML1, c-Myb, retinoic acid receptor α (RARα), and the CCAAT/enhancer binding protein (C/EBP) family (for review, see references (1) (2) . The C/EBP proteins are transcription factors belonging to the bZIP subgroup, which is characterized by the presence of a basic region involved in DNA binding and a leucine zipper region that mediates homo-and hetero-dimerization between family members (for review, see reference 3). Gene targeting studies in mice have revealed an essential role for several of these proteins in the development of specific blood cell lineages.
C/EBPβ deficient mice have defects in expansion of B lymphocytes (4) and produce dysfunctional monocytes, but have normal granulocytes (5) . C/EBPα deficient mice are blocked in granulocyte development at a very early stage; however, all other blood lineages, including blood monocytes and tissue macrophages, are normal by guest, on www.jbc.org Downloaded from 5 proteases in vivo has been illustrated by targeted deletion of the accessory subunit (capn4) that is required for activity of the ubiquitous calpain proteases. Capn4 null mice die during mid-gestation, apparently due to severe defects in the cardiovascular system accompanied by accumulation of erythroid progenitor cells (20) .
These data emphasize that calpain proteases play a major role in cell growth and differentiation. While calpains 1 and 2 are expressed in all tissues, calpain 3 is expressed at high levels in skeletal muscle and lens but is also found in various other tissues, where its physiological substrates are unknown (21) (22) (23) .
In this report, we present novel findings that implicate C/EBPα in regulating the expression and activity of calpain 3 in vivo. We have also identified a new physiological substrate for calpain 3: cyclin A.
We present evidence that cleavage of cyclin A by calpain 3 occurs in myeloid precursor cells and reveals a new pathway involving the tightly controlled post-translational processing of cyclin A.
EXPERIMENTAL PROCEDURES
Animals and tissue collection. Tissues from C/EBPα-/- (24) , C/EBPε-/-(7) and wild type littermates were harvested, immediately frozen in liquid nitrogen, and stored at -80 o C until analysis. Bone marrow was isolated from both femurs of adult animals as described (25) . CD33 + and CD15 + bone marrow cells were obtained from AllCells, L.L.C. Skeletal muscle was harvested from adult animals as a control for calpain 3 Northern analysis.
Construction of plasmids.
The plasmids pCS2 cyclin A WT-AU5, pCS2 cyclin A-mut5-AU5 (T   69   R   70   >A   69 A 70 ), and pcDNA3.1 cyclin A ∆1-70-AU1 have been previously described (26) . Cyclin A ∆1-120
and ∆1-130 were generated by PCR followed by subcloning into pCIneo (Promega). Cyclin A ∆120-130 was also generated by PCR using pCS2 cyclin A WT-AU5 as the template with the QuickChange protocol (Stratagene). pSRDp94 (calpain 3) was previously described (21) . The short cyclin A peptides used in these studies were generated by PCR using wild type cyclin A or cyclin A ∆120-130 as templates for cycApep and cycA∆pep, respectively. Primers contain sequences for alanine linkers and the nuclear localization sequence, by guest, on www.jbc.org
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as well as AgeI restriction sites. β-gal fusion proteins were generated by digesting cyclin A peptide PCR products with AgeI and ligating in frame at the AgeI site within pcDNA6/Myc-His/lacZ (Invitrogen).
Isolation of RNA and Northern analysis. Total RNA was isolated using RNA STAT 60 (Tel-Test "B", Inc.)
according to the manufacturer's protocol. Poly-A+ RNA was isolated using the Poly-A tract mRNA isolation system (Promega). Labeled calpain 3, C/EBPα, or GAPDH cDNAs were used as probes.
Isolation of cytoplasmic and nuclear proteins. Nuclei were isolated using a modification of our previously described hypotonic lysis protocol (27) . Briefly, tissues were homogenized in buffer A (25mM Tris-HCl pH 7.5, 50 mM KCl, 2 mM MgCl 2 , 1 mM EDTA, 5 mM DTT) containing Complete protease inhibitors (Boehringer Mannheim). In most experiments, 50 µM chymostatin was also included in buffer A (Chymostatin was not included in nuclear extract isolations to be used as a source of C/EBPα dependent cleavage activity as it inhibits this process.) The resulting nuclei were extracted by resuspending the nuclei in buffer B (25 mM Tris-HCl pH 7.5, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.5 mM EDTA, 1 mM DTT, 25% sucrose)
containing the same protease inhibitors used in buffer A (above). This mixture was incubated for 5 min. on ice and then centrifuged at 7,000 x g for 5 min. For analysis of the quality of protein extract preparations, the hypotonic lysis method described above was compared with a detergent lysis method described by Baer et al (28) . In some experiments, the detergent lysis method was also performed with the addition of chymostatin and Complete protease inhibitors. For preparation of whole cell extracts from primary or cultured hematopoietic cells, the protease inhibitors were added directly to the cell pellet, then the cells were lysed in Buffer B by passing the cells 10 times through an insulin syringe. The extract was cleared of cell debris by centrifugation at 10,000 rpm for 5 min. All extracts were stored at -80 o C.
Mixing experiments.
Mixing experiments were carried out by combining 50 µg of C/EBPα -/-newborn liver nuclear extract with 5 or 10 µg of wild type newborn liver nuclear extracts (final salt concentration was adjusted to 150 mM NaCl) and incubating at 37 o C for 30 min. 50 µg each of wild type or C/EBPα -/-extracts were incubated alone as controls. In some experiments, 50 µM chymostatin was included in the mixing 7 reaction, and in some experiments 0.5 units of purified m-calpain (Sigma) was added to the C/EBPα -/-sample.
Immunoblotting. Western analysis was carried out as previously described (27) . Polyclonal antibodies specific for the C-terminus of cyclin A (C-19), C/EBPα (14-AA), cdk2 (M-2) or the His epitope (G-18) are all from Santa Cruz Biotechnology. Monoclonal antibodies specific for β-galactosidase (clone D19-2F3-2) are from Roche. Polyclonal antisera against calpain 3 were generated against the peptide AENTISVDRPVKKKKNKPIIFVC (specific for the IS2 region of calpain 3; reference 21) and were affinity purified by chromatography with the immunogenic peptide covalently attached to sepharose. To verify protein loading, all blots were re-probed with antibodies specific to β-actin (monoclonal serum AC-74, Sigma).
In vitro cleavage assays. Cleavage assays were performed as described (27) 
RESULTS

Cyclin A is cleaved by a C/EBPα-dependent calpain.
An investigation of cell cycle related genes in C/EBPα knockout mice revealed that expression of full-length cyclin A is increased in newborn livers of C/EBPα-/-mice (31). Lower molecular weight cyclin A products were observed in the wild type tissues while only full length cyclin A is present in the C/EBPα knockout mice ( Fig 1A) . We had previously reported that a calpain-like activity was present in wild type newborn livers, but absent in the mice lacking the C/EBPα gene (27) . Therefore, we tested whether this activity might be responsible for the presence of the smaller cyclin A isoforms in the wild type tissue. To determine whether the truncated cyclin A found in vivo is due to cleavage of the full-length protein, and to determine if this cleavage activity is lacking in C/EBPα-/-animals, we performed mixing experiments. Nuclear extracts were isolated with PMSF only, and C/EBPα-/-newborn liver extracts were incubated with small amounts of wild type newborn liver extracts (see methods). Figure 1A shows that this leads to conversion of full length cyclin A to the same C-terminal truncated products observed in the wild type liver. It should be noted that the truncated cyclin A products are often observed as a doublet; however, in vitro cleavage assays revealed that the product 9 with slower mobility (approximately 40kDa) is converted to the approximately 38kDa molecule (data not shown), resulting in one major cleavage product. We refer to this product as A38. Interestingly, the truncated products are stable in the wild type extracts during incubation ( Figure 1A , 1 st lane) and accumulate in the C/EBPα-/-extracts after mixing ( Figure 1A , 4 th lane), suggesting they are more stable than the full-length protein. These data show that cyclin A is cleaved by a protease that is not active in C/EBPα-/-mice. To investigate the identity of the protease, a set of protease inhibitors was examined. Cleavage of cyclin A was completely inhibited by the addition of chymostatin to the mixing experiment ( Figure 1B ). These data are consistent with our previous findings that C/EBPα regulates a calpain protease in the newborn liver (27) . To determine if calpain cleaves cyclin A, we incubated purified calpain with C/EBPα-/-extracts. Addition of this protease is sufficient to generate the same truncated forms of cyclin A that are found in the wild type newborn liver ( Figure 1C ).
To verify that the cleavage of cyclin A occurs in vivo and is not an artifact of protein isolation, we isolated nuclear extracts using several different methods. We used our standard hypotonic lysis procedure as well as a lysis buffer containing NP-40 that was previously described to inhibit proteolysis during the extraction procedure (28) . Additionally, both lysis procedures were carried out in the absence or in the presence of the Complete protease inhibitor cocktail (Roche) and chymostatin, since it inhibits the protease that cleaves cyclin A. Figure 1D shows the presence of cyclin A cleavage products in newborn liver nuclear extracts with each isolation procedure. As can be seen, the hypotonic lysis procedure in the presence of
Complete protease inhibitors and chymostatin results in an extract that contains the most full length cyclin A protein.
To verify that the protease was inhibited during extract preparation, we subsequently carried out cyclin A cleavage assays. Figure 1E shows incubation of radiolabeled cyclin A with the different preparations of nuclear extract from newborn liver. We found that extracts isolated with the hypotonic lysis buffer in the presence of protease inhibitors are not able to cleave cyclin A, while the other preparations are much less effective, or not at all effective in inhibiting the protease activity. Our data show that this isolation procedure produces an extract in which the protease that cleaves cyclin A is inhibited; therefore it is unlikely that cyclin A cleavage occurs during cell extraction. Unless otherwise noted, all extracts were prepared in this manner.
C/EBPα-dependent cleavage of cyclin A occurs in myeloid precursor cells.
Given the observation that C/EBPα regulates cleavage of cyclin A in newborn liver, we tested for the protease activity in other tissues from newborn mice, some of which express high levels of C/EBPα. Tissues tested include heart, lung, stomach, intestine, kidney, thymus, spleen, brown adipose tissue, eye, and brain. Only extracts from newborn livers and spleens were able to cleave cyclin A. The protease activity was found in the spleen of newborn mice and within one week of birth, but disappeared after 7 days of age. No cleavage activity toward cyclin A was found in spleens of older animals (data not shown). Since fetal and newborn liver and spleen are primary sites for hematopoiesis until the bone marrow is developed, we tested whether adult bone marrow possesses the protease activity. Figure 2A shows that bone marrow (BM) contains robust cleavage activity toward cyclin A, suggesting that hematopoietic precursor cells are in fact a major source of the C/EBPα-dependent calpain protease activity in vivo.
To determine whether cleavage of cyclin A is specific to a certain lineage of hematopoietic precursor cells, we carried out cyclin A cleavage assays in the presence of cellular extracts derived from several hematopoietic cell lines, including BJAB (human B cell non-Hodgkin lymphoma), Raji (human B cell Burkitt lymphoma), M1 (mouse myeloblastic leukemia, p53-/-), KG1a (human CD34+ myelomonocytic), and RPMI-8402 (human pre-T cell). Of the cell lines tested, only U937 and KG1a produced a detectable cyclin A cleavage product ( Figure 2B ). These data suggested that the protease that cleaves cyclin A is preferentially Western analysis revealed the presence of cleaved cyclin A in both subsets of myeloid precursor cells, although cleavage of cyclin A was more prevalent in CD15 + bone marrow cells ( Figure 2D ). Cleaved cyclin A was detectable in CD33 + cells when more extract was loaded. The migration of the cleaved form of cyclin A in normal human myeloid precursor cells is indistinguishable from that found in U937 cells and in newborn mouse liver, and it is detectable in all of these cells following direct lysis and boiling in SDS sample buffer (data not shown). To confirm that CD33+ and CD15+ cells contain protease activity toward cyclin A, a cleavage assay was carried out using whole cell extracts from these cells as well as extract from whole bone marrow (all isolated with PMSF only). All of these extracts were capable of cleaving cyclin A ( Figure 2E ).
These data show that normal myeloid precursor cells contain cleaved cyclin A and confirm our observations made in newborn mouse liver.
Calpain-mediated cleavage of cyclin A occurs between amino acids 120-130.
It was previously described that cyclin A can be cleaved in vitro by a p27-dependent protease, generating an Nterminally truncated, active molecule (26) . However, it was subsequently determined that the protein responsible for this cleavage of cyclin A was bacterial OmpT, which co-purified with p27 plasmid DNA (32).
Since calpain-mediated proteolysis of cyclin A also leads to the production of an N-terminally truncated product, we compared the sites of proteolysis. A cyclin A construct that contains point mutations at amino acids 69 and 70 (cyclin A T 69 R 70 >AA) and cannot be cleaved by OmpT (26) , was tested in a cleavage assay.
Using cyclin A or cyclin A T 69 R 70 >AA as substrates, we found that addition of wild type newborn liver or spleen extracts to either the mutant or wild type cyclin A leads to the appearance of the truncated cyclin A cleavage product ( Figure 3A) . Addition of C/EBPα-/-extracts has no effect on the stability of either protein ( Figure 3A ), since the calpain activity is absent in these mice. Incubation of cyclin D1 in a similar assay does not lead to cleavage of this protein, suggesting that cyclin A may be a specific substrate for the C/EBPα-dependent calpain. This observation is consistent with the fact that protein levels of cyclin D1 are not altered in C/EBPα-/-mice compared to wild type littermates (data not shown). These data also confirm previous data that C/EBPα-dependent proteolysis is not due to global protein degradation (27) .
To determine the site of cyclin A cleavage, we generated several N-terminally truncated forms of the Figure 3D ). Reprobing the same membrane with antibodies specific for the His tag ensured that the C-terminus is absent after cleavage. These data verify that the site of C/EBPα-cleavage is located between amino acids 120 and 130, and that a short region surrounding the cleavage site (amino acids 109-141) is sufficient for calpain-mediated proteolysis. Similar results were obtained when the fusion protein was incubated with purified calpain (data not shown).
Calpain 3 cleaves cyclin A and is differentially expressed in C/EBPα-/-mice.
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We initially found that another member of the C/EBP family, C/EBPβ, was cleaved by a calpain protease in the newborn liver and that the activity of the calpain was dependent on C/EBPα. Analysis of inhibitors of the C/EBPα-dependent calpain, as well as its calcium independent activity ( Figure 1D and reference 27),
suggested that the calpain in newborn liver is similar to calpain 3 (also referred to as nCL-1 or p94; for review, see references 16 and 33). Calpain 3 is a unique, rather unstable, calcium-independent protease that has been extensively characterized in skeletal muscle (21, 22) . To determine if expression of calpain 3 is altered in C/EBPα-/-mice, poly-A+ mRNA was isolated from pooled newborn livers. Northern analysis was carried out using a probe consisting of nearly full-length calpain 3 cDNA. As shown in Figure 4A , calpain 3 mRNA was detected in wild type newborn liver. This mRNA is absent in newborn livers of C/EBPα-/-mice, and is approximately 2.8 kb, versus the 3.5 kb calpain 3 mRNA found in skeletal muscle ( Figure 4B ). The 2.8 kb calpain 3 mRNA is expressed in newborn liver at very low levels compared to full-length calpain 3 expression in skeletal muscle ( Figure 4B , 1 st lane). To determine if calpain 3 protein levels are altered in C/EBPα-/-mice, we carried out Western blotting using an antibody specific for the unique IS2 region of calpain 3 (21) . In agreement with Northern analysis, we detected an approximately 80 kDa protein that is expressed in wild type but not in C/EBPα -/-newborn liver ( Figure 4C ). The differentially expressed mRNA and protein are of the appropriate size to be a splice variant of calpain 3 that lacks exon 6 and possibly exons 15 and 16, which are often excluded as well (34) . Variants of calpain 3 that lack exon 6 are more stable than the full-length protein because two of the three sites of autolysis are located in this region (21, 34, 35) . We did not detect the 94 kDa calpain 3 protein in newborn liver nuclear extracts, which may be due to its rapid autolysis (21) or low expression in this tissue.
Cyclin A cleavage assays in the presence of C/EBPα-/-and +/+ extracts show that the C/EBPα dependent calpain is calcium independent, is inhibited by chymostatin but is not fully inhibited by EDTA, calpastatin, or E-64 ( Figure 4D ). As in Figure 3B, Figure 4D ). Taken together, these data show that expression of a variant of calpain 3 is regulated by C/EBPα in vivo. Furthermore, the biochemical behavior of this calpain is more similar to calpain 3 than to calpains 1 or 2.
To confirm that calpain 3 is the protease responsible for cleavage of cyclin A, we immunoprecipitated calpain 3 from wild type or C/EBPα-/-newborn livers and assessed its ability to cleave cyclin A. We found that two different affinity-purified antibodies to calpain 3 could immunoprecipitate the protease activity, although the S21Q antibody was consistently able to precipitate more calpain 3 protease activity. The immunoprecipitated calpain 3 was able to cleave cyclin A but not cyclin A ∆120-130 ( Figure 5A ). As expected, no cleavage activity was detected when C/EBPα-/-extracts were used for calpain 3
immunoprecipitations.
To understand whether calpain 1 and/or calpain 2 could also contribute to cleavage of cyclin A in vivo, we measured the relative activity of calpains 1 and 2 in wild type and C/EBPα-/-newborn livers by casein zymography (30) . Figure 5B shows that activity of calpain 2 is not altered in the absence of C/EBPα; however, calpain 1 activity is induced in newborn livers of C/EBPα-/-animals. These data suggest that although calpains 1 and 2 are both present and active in C/EBPα-/-animals, they do not cleave cyclin A in 15 vivo. Immunoprecipitates using antibodies specific for calpains 1 and 2 were unable to cleave cyclin A in cleavage assays, even in the presence of calcium ( Figure 5C ). Also, addition of calcium to intact C/EBPα-/- Truncated cyclin A interacts with cdk2 to form an active complex.
Next, we characterized the biological activity of truncated cyclin A by examining whether it forms active complexes with cdk2. Newborn liver extracts were isolated by hypotonic lysis with no protease inhibitors, followed by incubation at 37 o C for 10 minutes to ensure that cyclin A was completely cleaved in vitro. Using this method, nuclear extracts from wild type or C/EBPα heterozygous newborn livers contain no detectable full length cyclin A protein, while extracts from C/EBPα-/-mice contain abundant full-length cyclin A and little or no cleavage product ( Figure 6A ). Next, cyclin A was immunoprecipitated from these extracts and tested for associated cdk2 activity using histone H1 (HH1) as a substrate. Despite the striking differences in the forms of cyclin A present in wild type versus C/EBPα-/-extracts, we found no significant difference in the ability of the cyclin A to bind and activate cdk2 ( Figure 6B , top). To verify equal loading of HH1 in each reaction, filters were stained with Coomassie blue after autoradiography ( Figure 6B , bottom). Quantitation of seven experiments using 3 pairs of animals showed no significant difference in cyclin A-associated cdk2 activity between wild type and C/EBPα-/-littermates. These results show that truncated cyclin A is an active protein that is able to bind and activate cdk2. This is in agreement with previous data showing the region of cyclin A that is required for cyclin-dependent kinase interaction and activation ( Figure 6C and reference 37).
DISCUSSION
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In this report, we describe a novel pathway for post-translational processing of cyclin A by calpain 3 in myeloid precursor cells. We have characterized the proteolysis of cyclin A and have found that, of all mouse tissues tested, it is restricted to tissues containing hematopoietic precursor cells, such as fetal and newborn liver and spleen and adult bone marrow. Cleaved cyclin A is also detectable in normal human myeloid precursor cells. Our data demonstrate that C/EBPα regulates this pathway, as C/EBPα-/-mice are lacking the protease activity and are lacking detectable calpain 3 mRNA and protein. The absence of the protease is not simply due to the absence of mature granulocytes in these mice, since C/EBPε-/-mice, which have defects at the latest stage of granuloctye differentiation, retain calpain 3 activity (data not shown). It is unknown whether the regulation of calpain 3 by C/EBPα is due to direct regulation of transcription, but it is probable that another factor cooperates with C/EBPα to regulate the protease in these cells since non-myeloid tissues that contain high levels of C/EBPα, such as adult liver and adipose tissue, do not contain the calpain 3 activity that cleaves cyclin A.
Calpain 3 is expressed mainly in skeletal muscle (21) , and mutations in calpain 3 have been shown to result in limb girdle muscular dystrophy type 2A in humans (35, 36) . However, it has not been described that mutation of calpain 3 in humans results in any abnormal hematopoietic phenotype. Several splice variants of calpain 3 have been described, some of which affect the stability of the protease (35, 36) , and at least one of which utilizes an alternative promoter (38) . In this report, we have shown that at least one splice variant of calpain 3 (∆ex 6,15,16) can specifically cleave cyclin A. It is interesting to note that mouse skeletal muscle, which produces mainly the full-length, highly unstable form of calpain 3 (21), does not contain detectable proteolytic activity toward cyclin A (data not shown). Further investigations with respect to alternative splicing and/or alternative promoter usage of calpain 3 during myeloid differentiation will reveal the relationship between C/EBPα and calpain 3 expression. Although calpain 3 clearly cleaves cyclin A in myeloid cells, many new calpain family members have been identified that have not yet been characterized with respect to protein expression or proteolytic activity (39) . At this time, we cannot rule out that one or more of the novel calpains may also cleave cyclin A, although no cleavage is detected in newborn livers in the absence of C/EBPα.
Importantly, lack of calpain 3-mediated cyclin A cleavage does not appear to be compensated by calpains 1 and 2 in vivo, as the activity of calpain 1 is elevated in newborn livers of C/EBPα-/-mice and the activity of calpain 2 is unchanged. These data strongly suggest that, in vivo, calpain proteases have distinct substrate specificities.
The calpain system is involved in cleavage of another cyclin protein in Alzheimers disease, where an undetermined calpain cleaves the cyclin-like protein p35, which is the activator of cdk5 in the brain (40, 41) . (C) Cyclin A cleavage assay using no extract (-), extracts from wild type newborn liver (+/+), or immunoprecipitates using pre-immune serum (PI) or antibodies to calpain 3 (3), calpain 2 (2), or calpain 1 (1).
Immunoprecipitations were carried out with either +/+ or C/EBPα-/-newborn liver extracts. Some reactions contained 10mM CaCl 2 (shown below the gel). The slight shift in the mobility of full-length cyclin A is due to the co-migration of IgGs. 
